Merck & Co

Merck EVP Hans-Joachim Neumann says India's industrial base and skilled talent make it globally competitive as Merck signs pact with Tata Electronics to boost semiconductor capabilities

The company expects labs at the new facility to be fully operational by 2028 and produce experimental drugs by 2030

The company, through one of its subsidiaries, will pay $200 per share for Prometheus Biosciences

Molnupiravir, developed by Merck with partner Ridgeback Biotherapeutics LP, is intended to treat Covid in nonhospitalized people 18 and older at risk of developing severe illness

Permission for Merck & Co's antiviral treatment would likely be limited to patients at high risk of developing severe disease, although the exact population would be defined by the agency.

The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug

An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization

Acceleron shareholders will get $180 a share in cash, the companies said in a statement.

(Reuters) - Merck & Co reported quarterly revenue on Thursday that topped Wall Street estimates, as sales of its Gardasil vaccine bounced back and demand for blockbuster cancer drug Keytruda remained strong.

Clinical trial shows molnupiravir helps in early recovery in non-hospitalised Covid-19 patients

Merck has decided to focus on its drugs for Covid after two vaccines failed to generate desired immune responses

(Reuters) - U.S. drugmaker Merck & Co said on Wednesday it has sold its equity investment in Moderna Inc, after benefiting from a surge in the stock price of the vaccine developer this year.

Initial data showing whether V591 triggers an immune response in trial participants is expected by the end of the year

Some of the world's most prolific and experienced vaccine developers -- Sanofi, GlaxoSmithKline and Merck & Co - are among at least 100 challengers trailing the leaders

Merck's biosimilars business could be worth as much as $1 billion because of its long-term sales potential.

The pharmaceutical companies are developing the drug ertugliflozin for use alone and in combination with Merck's best-selling Januvia